Peptides / Weight and metabolic

Synthetic analog · 36 amino acids · 4,192 Da

Petrelintide

Not approvedBanned in sport

Petrelintide is an experimental long-acting amylin analog studied for weight management, in phase 3 trials, not approved and banned in sport as an unapproved substance. Studies in people tested it on body weight and tracked stomach and other side effects. PepBank shows 22 results on petrelintide from 2 studies in people. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as RO7895515, ZP-8396, ZP8396

Evidence level: Large trials in people22 of 22 results come from studies in people, including randomized trials.

Results in people

100% of 22 results

Results in animals

0% of 22 results

Results in lab cells

0% of 22 results

From computer models

0% of 22 results

Overview

Petrelintide at a glance

What it is	Synthetic analog, 36 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S0)
Studies	2 studies with results. Both of them gave petrelintide, with 22 results. 22 in people
Best study in people	Randomized controlled trial with 485 people (2026)
Clinical trials	12 registered: 6 active or planned, 0 with posted results

The science

What is petrelintide?

A long-acting amylin analog studied for weight management.

Amino acids in one chain

The history of petrelintide

2021October
A registered trial of petrelintide started (NCT05096598).
2025
The oldest paper on petrelintide in PepBank is from 2025.

Petrelintide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Petrelintide is a synthetic analog of 36 amino acids, with a ring, 5 changed amino acids.

Formula

C₁₈₅H₃₀₅N₄₉O₆₁

Molecular weight

4,192 g/mol

CAS number

2766385-23-1

Target

Calcitonin receptor and amylin receptor complexes (gene CALCR): agonistEvidence: Peptide 40 activated human CTR and human AMY3R in cAMP assays.

Development

Zealand Pharma / Roche. Highest phase: phase 3.

Identifiers

PubChem 172915807, ChEMBL CHEMBL5314864, UNII D78KBY7BRU, DrugBank DB19442

SMILES and InChIKey

Three-letter sequence
gamma-Glu-Arg-Asp-Gly-Thr-Ala-Thr-Lys-Ala-Thr-Glu-Arg-Leu-Ala-Aad-Phe-Leu-Gln-Arg-Ser-Ser-Phe-N-Me-Gly-Ala-N-Me-Ile-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-Asn-Thr-Hyp-NH2

See charge, composition and 3D structure on the Scientific page

The evidence

What petrelintide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people22 of 22 results come from studies in people, including randomized trials.

Weight and appetite

7 results · 7 in people

In adults with overweight or obesity, weight decreased 9·8% with petrelintide 5·0 mg versus 1·7% with placebo at 28 weeks. The lancet. Diabetes & endocrinology, 2026

Survival and serious illness

1 result · 1 in people

In the obesity trial, no deaths were reported, including during petrelintide treatment. The lancet. Diabetes & endocrinology, 2026

All 2 studies in people

In people

In adults with overweight or obesity, nausea occurred in 20% with petrelintide versus 6% with placebo.

2026The lancet. Diabetes & endocrinology485 people

In people

In phase 1 participants, digestive disorders were among the most common petrelintide side effects and were mostly mild.

2026Diabetes, obesity & metabolism

All 2 petrelintide studies by area Open the Scientific page

Key petrelintide studies

Studies in people come first, then studies in animals and in the lab.

People
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial
Garvey et al. 2026 · The lancet. Diabetes & endocrinology · 485 people · cited by 0
11 results
People
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
Brændholt et al. 2026 · Diabetes, obesity & metabolism · cited by 2
11 results

All 2 Petrelintide studies

Petrelintide clinical trials

ClinicalTrials.gov lists 12 trials of petrelintide. 6 are active or planned, and 0 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

Phase 3recruiting3,900 planned

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Phase 3recruiting2,500 planned

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Phase 3recruiting600 planned

1 Petrelintide trial

Status and safety

Is petrelintide approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S0.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026). Banned in sport (WADA S0).

Laws and labels change, so check the regulator for the current status.

Petrelintide side effects and safety

PepBank has 12 safety results from studies of petrelintide. 12 of them come from studies in people.

Safety results from studies (12)

In adults with overweight or obesity, nausea occurred in 20% with petrelintide versus 6% with placebo. (The lancet. Diabetes & endocrinology, 2026)
In phase 1 participants, no serious adverse events emerged during petrelintide treatment. (Diabetes, obesity & metabolism, 2026)
In adults with overweight or obesity, vomiting occurred in 3% with petrelintide versus 6% with placebo. (The lancet. Diabetes & endocrinology, 2026)
In adults with overweight or obesity, diarrhoea occurred in 7% with petrelintide and 7% with placebo. (The lancet. Diabetes & endocrinology, 2026)
In adults with overweight or obesity, constipation occurred in 7% with petrelintide versus 4% with placebo. (The lancet. Diabetes & endocrinology, 2026)
In the obesity trial, no deaths were reported, including during petrelintide treatment. (The lancet. Diabetes & endocrinology, 2026)
In phase 1 participants, no severe adverse events emerged during petrelintide treatment. (Diabetes, obesity & metabolism, 2026)
In phase 1 participants, digestive disorders were among the most common petrelintide side effects and were mostly mild. (Diabetes, obesity & metabolism, 2026)
One phase 1 participant stopped petrelintide because of digestive side effects. (Diabetes, obesity & metabolism, 2026)
In MAD part 2, nausea affected 16.7%-33.3% with petrelintide versus 16.7% with placebo. (Diabetes, obesity & metabolism, 2026)
In phase 1 participants, diarrhoea was rare during petrelintide treatment. (Diabetes, obesity & metabolism, 2026)
In phase 1 participants, only the person who stopped petrelintide experienced vomiting. (Diabetes, obesity & metabolism, 2026)

See every safety result on the Scientific page

Doses studied (5 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
5·0 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 164	Garvey 2026
9·0 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 163	Garvey 2026
2·5 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 162	Garvey 2026
1·0 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 160	Garvey 2026
7·0 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 160	Garvey 2026

Questions and more

Ask a question about petrelintide

The answer links to every study it uses.

What does the evidence say about petrelintide?Is petrelintide tested in people?Compare with Semaglutide Compare with Liraglutide

Sources

Database: PepBank data for petrelintide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about petrelintide

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Petrelintide

Petrelintide at a glance